do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance guideline The effect of DPP DPP4 Inhibitor Mechanism of Action

Description

Adult patients with T2DM treated by metformin, thiazolidinediones/rosiglitazone or both without adequate glycaemic control after 3 months were enrolled in SUSTAIN 2 trial to explore the comparative effectiveness of semaglutide against sitagliptin

Chen, W

[45] enrolled 34 insulin and incretin-nave T2D patients on metformin and randomized subjects to exenatide or insulin glargine treatment arms

GLP-1 receptor agonists such as exenatide, liraglutide, semaglutide, and dulaglutide are already approved for treating Type 2 diabetes mellitus and obesity, which interests researchers in further research

Abstract This review provides a comprehensive examination of the clinical pharmacological mechanisms and broad therapeutic applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual receptor agonists targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors